CLAIMS

We claim:

1. The use of a recombinant modified Vaccinia Ankara (MVA) virus for the manufacture of a medicament for inducing a robust CD8 T cell response against a neoantigen in a human;

wherein the recombinant MVA comprises a Pr13.5 promoter operably linked to a nucleotide sequence encoding the neoantigen,

wherein the Pr13.5 promoter comprises at least 1 copy of a nucleic acid sequence of at least 40 bases having at least 95% identity with SEQ ID NO:1; ~~and~~

wherein the Pr13.5 promoter comprises at least 1 copy of a second nucleotide sequence of at least 31 nucleotides that has at least 95% identity with SEQ ID NO:1; and wherein the Pr13.5 promoter comprises 2 copies of a nucleotide sequence of at least 40 nucleotides that has 100% identity with SEQ ID NO:1.

2. The use of claim 1, wherein the Pr13.5 promoter comprises at least 1 copy of a nucleic acid sequence of at least 40 bases having at least 98% identity with SEQ ID NO:1.

3. The use of claim 1, wherein the Pr13.5 promoter comprises at least 1 copy of a nucleic acid sequence of at least 40 bases having 100% identity with SEQ ID NO:1.

4. The use of claim 1, wherein the Pr13.5 promoter comprises at least 1 copy of a second nucleotide sequence of at least 31 nucleotides that has at least 98% identity with SEQ ID NO:1.

5. The use of claim 1, wherein the Pr13.5 promoter comprises at least 1 copy of a second nucleotide sequence of at least 31 nucleotides that has 100% identity with SEQ ID NO:1.

6. The use of claim 1, wherein the Pr13.5 promoter comprises SEQ ID NO:2.

7. A recombinant modified Vaccinia Ankara (MVA) virus comprising a Pr13.5 promoter operably linked to a nucleotide sequence encoding a neoantigen,

wherein the Pr13.5 promoter comprises at least 1 copy of a nucleic acid sequence of at least 40 bases having at least 95% identity with SEQ ID NO:1 and wherein the Pr13.5 promoter comprises at least 1 copy of a second nucleotide sequence of at least 31 nucleotides that has at least 95% identity with SEQ ID NO:1; and wherein the Pr13.5 promoter comprises 2 copies of a nucleotide sequence of at least 40 nucleotides that has 100% identity with SEQ ID NO:1.

8. The recombinant MVA of claim 7, wherein the Pr13.5 promoter comprises at least 1 copy of a nucleic acid sequence of at least 40 bases having at least 98% identity with SEQ ID NO:1.

9. The recombinant MVA of claim 7, wherein the Pr13.5 promoter comprises at least 1 copy of a nucleic acid sequence of at least 40 bases having 100% identity with SEQ ID NO:1.

10. The recombinant MVA of claim 7, wherein the Pr13.5 promoter comprises at least 1 copy of a second nucleotide sequence of at least 31 nucleotides that has at least 98% identity with SEQ ID NO:1.

11. The recombinant MVA of claim 7, wherein the Pr13.5 promoter comprises at least 1 copy of a second nucleotide sequence of at least 31 nucleotides that has 100% identity with SEQ ID NO:1.

12. The recombinant MVA of claim 7, wherein the Pr13.5 promoter comprises SEQ ID NO:2.